NEWS

Handa Pharmaceuticals, Inc. Announces Launch of Proprietary ONCORE® Oncology Drug Delivery Technology Platform

2018-07-17

Handa Pharmaceuticals Announces TruPharma’s U.S. Launch Of Its FDA-Approved ANDA for Lamotrigine Extended Release Tablets

2017-06-06

Handa Pharmaceuticals, Inc. Announces FDA Approval for Generic Version of AstraZeneca’s SEROQUEL XR® Extended Release Tablets

2017-05-10

Taiwan Authorities Approve Public Issuance of Handa Stock

2016-11-23

Handa Pharmaceuticals Announces Endo Begins Shipping Generic Version of AstraZeneca’s SEROQUEL XR®

2016-12-01

Pharmira Laboratories, Inc. Merges With Handa Pharmaceuticals, LLC

2016-02-01

Handa Pharmaceuticals Announces Tentative Approval of First-to-File ANDA for Takeda’s DEXILANT®

2013-12-26

Handa Pharmaceuticals Announces Acquisition and License Agreement with Par Pharmaceutical for Its First-to-File ANDA for AstraZeneca’s SEROQUEL XR®

2012-10-29

Handa Pharmaceuticals Announces Acquisition and License Agreement with Par Pharmaceutical for Its First-to-File ANDA for Takeda’s DEXILANT®

2012-04-09

Handa Pharmaceuticals Announces Patent Litigation Settlement With AstraZeneca On its First-to-File ANDA for SEROQUEL XR®

2011-10-03

Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takeda’s DEXILANT®

2011-03-02

Handa Pharmaceuticals Announces Tentative Approval of its First-to-File ANDA for AstraZeneca’s SEROQUEL XR®

2010-12-30

Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZeneca’s SEROQUEL® XR

2008-07-31